HLS Therapeutics Q4 2023 Earnings Report C$4.17 -0.02 (-0.48%) As of 02/21/2025 03:39 PM Eastern Earnings HistoryForecast HLS Therapeutics EPS ResultsActual EPS-C$0.18Consensus EPS -C$0.13Beat/MissMissed by -C$0.05One Year Ago EPSN/AHLS Therapeutics Revenue ResultsActual Revenue$21.60 millionExpected Revenue$21.83 millionBeat/MissMissed by -$230.00 thousandYoY Revenue GrowthN/AHLS Therapeutics Announcement DetailsQuarterQ4 2023Date3/14/2024TimeN/AConference Call ResourcesHLS Earnings History HLS Therapeutics Earnings HeadlinesTop Canadian Pharmaceutical Stocks of 2025February 3, 2025 | fool.caOptimistic Buy Rating for HLS Therapeutics Despite Revenue ChallengesNovember 10, 2024 | markets.businessinsider.com My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blueprint. And I have something surprising to tell you about it … It doesn't include Nvidia.February 22, 2025 | Weiss Ratings (Ad)HLS Therapeutics Third Quarter 2024 Earnings: Misses ExpectationsNovember 8, 2024 | finance.yahoo.comHLS Therapeutics Inc (HLTRF) Q3 2024 Earnings Call Highlights: Strategic Debt Reduction and ...November 8, 2024 | finance.yahoo.comHLS Therapeutics Inc (TSX:HLS) Q3 2024: Everything You Need To Know Ahead Of EarningsNovember 6, 2024 | finance.yahoo.comSee More HLS Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like HLS Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on HLS Therapeutics and other key companies, straight to your email. Email Address About HLS TherapeuticsHLS Therapeutics (TSE:HLS), a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease. It also distributes MyCare psychiatry lab assays; and MyCare Insite, a point-of-care device to measure patient drug levels. In addition, the company holds the Canadian rights of Trinomia, a cardiovascular therapeutic; and a portfolio of royalty interests of four healthcare products. HLS Therapeutics Inc. is headquartered in Etobicoke, Canada.View HLS Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles The Trade Desk Crashes on Earnings, But Growth Catalysts PersistHims & Hers Earnings Could Be a Game Changer—What to Do NowAnalysts See Buying Opportunity in NVIDIA Before EarningsAirbnb's Earnings: Sky High Results, Grounded Guidance?Is Coinbase Stock a Buy After Earnings?CVS Health: Earnings Beat Ignites Stock RallyQualcomm’s Post-Earnings Dip: A Prime Buying Opportunity? Upcoming Earnings Workday (2/24/2025)Intuit (2/25/2025)American Tower (2/25/2025)Bank of Montreal (2/25/2025)Bank of Nova Scotia (2/25/2025)Public Storage (2/25/2025)NVIDIA (2/26/2025)Synopsys (2/26/2025)Salesforce (2/26/2025)Lowe's Companies (2/26/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
